X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1031) 1031
Publication (136) 136
Patent (13) 13
Book Chapter (9) 9
Book Review (6) 6
Conference Proceeding (5) 5
Book / eBook (4) 4
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (547) 547
oncology (418) 418
male (337) 337
female (334) 334
middle aged (298) 298
cancer (283) 283
index medicus (279) 279
aged (261) 261
adult (228) 228
chemotherapy (208) 208
adenocarcinoma (197) 197
surgery (182) 182
esophageal cancer (155) 155
prognosis (135) 135
antineoplastic combined chemotherapy protocols - therapeutic use (132) 132
esophageal neoplasms - pathology (132) 132
adenocarcinoma - pathology (116) 116
carcinoma (116) 116
care and treatment (113) 113
treatment outcome (112) 112
stomach neoplasms - drug therapy (111) 111
aged, 80 and over (110) 110
combined modality therapy (109) 109
stomach cancer (109) 109
esophageal neoplasms - therapy (100) 100
neoplasm staging (100) 100
retrospective studies (100) 100
survival (98) 98
stomach neoplasms - pathology (97) 97
gastric cancer (95) 95
chemoradiotherapy (90) 90
adenocarcinoma - drug therapy (89) 89
esophageal neoplasms - drug therapy (88) 88
survival rate (88) 88
adenocarcinoma - therapy (87) 87
chemoradiation (79) 79
esophageal neoplasms - mortality (79) 79
fluorouracil - administration & dosage (78) 78
radiotherapy (78) 78
research (76) 76
article (73) 73
adenocarcinoma - mortality (72) 72
survival analysis (72) 72
therapy (68) 68
cisplatin - administration & dosage (65) 65
medicine & public health (65) 65
squamous-cell carcinoma (64) 64
neoadjuvant therapy (63) 63
antineoplastic agents - therapeutic use (56) 56
metastasis (56) 56
esophageal neoplasms - surgery (55) 55
patient outcomes (55) 55
adenocarcinoma - surgery (53) 53
disease-free survival (53) 53
fluorouracil (51) 51
chemotherapy, adjuvant (50) 50
esophageal neoplasms - radiotherapy (50) 50
esophagogastric junction (50) 50
cisplatin (49) 49
gastrectomy (48) 48
randomized-trial (48) 48
stomach neoplasms - therapy (48) 48
abridged index medicus (47) 47
health aspects (47) 47
stomach neoplasms - mortality (47) 47
esophagus (46) 46
stomach neoplasms - surgery (46) 46
phase-iii trial (44) 44
analysis (43) 43
esophagectomy (43) 43
follow-up studies (41) 41
antineoplastic combined chemotherapy protocols - adverse effects (40) 40
preoperative chemoradiation (40) 40
risk factors (40) 40
animals (39) 39
gastroenterology & hepatology (39) 39
patients (39) 39
5-fluorouracil (37) 37
cell biology (37) 37
drug administration schedule (36) 36
stomach neoplasms - genetics (36) 36
surgical oncology (36) 36
trial (36) 36
tumors (36) 36
adenocarcinoma - genetics (35) 35
esophageal neoplasms - genetics (35) 35
lymphatic metastasis (35) 35
phase-ii trial (35) 35
proportional hazards models (35) 35
breast-cancer (34) 34
carcinoma, squamous cell - therapy (34) 34
expression (33) 33
radiology, nuclear medicine & medical imaging (33) 33
esophagogastric junction - pathology (32) 32
adenocarcinoma - radiotherapy (31) 31
carcinoma, squamous cell - drug therapy (31) 31
radiation (31) 31
carcinoma, squamous cell - pathology (30) 30
mortality (30) 30
multivariate analysis (30) 30
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1224 - 1235
Summary Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | ONCOLOGY | BEVACIZUMAB | CLINICAL-TRIALS | GROWTH | 2ND-LINE CHEMOTHERAPY | OPEN-LABEL | 1ST-LINE THERAPY | COMBINATION | CANCER | III TRIAL | Confidence Intervals | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Esophageal Neoplasms - mortality | Adult | Female | Remission Induction - methods | Paclitaxel - administration & dosage | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Paclitaxel - adverse effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Hospitals | Clinical trials | Monoclonal antibodies | Product development | Antineoplastic agents | Vascular endothelial growth factor | Esophageal cancer
Journal Article
Nature Reviews Gastroenterology and Hepatology, ISSN 1759-5045, 02/2013, Volume 10, Issue 2, pp. 109 - 118
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2019, p. clincanres.2585.2019
Journal Article
Gastroenterology, ISSN 0016-5085, 09/2018, Volume 155, Issue 3, pp. 934 - 935
Journal Article
Gastroenterology, ISSN 0016-5085, 09/2018, Volume 155, Issue 3, pp. 934 - 935
Journal Article
Gastroenterology, ISSN 0016-5085, 09/2018, Volume 155, Issue 3, pp. 934 - 935
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2019, Volume 37, Issue 30, pp. 2805 - 2806
Journal Article
Journal Article
2005, M.D. Anderson cancer care series, ISBN 9780387220901
Web Resource
2005, M.D. Anderson cancer care series, ISBN 9780387220901
Web Resource